HB0036

HB0036 is an investigational agent whose form is not stated in the registry developed by Shanghai Huaota Biopharmaceutical. Its targets are PD-L1 and TIGIT (the sponsor names PD-L1 x TIGIT). The sponsor states: HB0036 is an anti-PD-L1/anti-TIGIT bifunctional antibody molecule, given by intravenous infusion every three weeks, simultaneously engaging both checkpoint pathways. ClinicalTrials.gov describes the intervention as: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05417321, plans to enrol 80 participants with primary completion expected 2025-08-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.